GlassScriptPhysician profile
Dale A Menard
NPI 1629031323
$5,298.27
in general payments reported to CMS, 2019-2025
56 companies · $1,911 in 2025
The $1,911 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $300 · 2021: $295 · 2022: $352 · 2023: $349 · 2024: $1,153 · 2025: $1,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,334 · Education: $78.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,334.17 |
| Education | $78.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $958.28 | 2019-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $768.42 | 2021-2025 | |
| Pfizer INC. | $523.35 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $247.60 | 2019-2025 | |
| Ucb, INC. | $173.90 | 2019-2024 | Rystiggo, Briviact |
| Emd Serono, INC. | $168.58 | 2019-2025 | |
| Amgen INC. | $143.44 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $119.90 | 2019-2021 | |
| Mdd US Operations, LLC | $112.98 | 2019-2025 | Apokyn |
| Csl Behring | $111.74 | 2024-2025 | Hizentra |
| Avadel Cns Pharmaceuticals, LLC | $107.04 | 2023-2025 | Lumryz |
| Genzyme Corporation | $102.67 | 2019 | |
| Jazz Pharmaceuticals INC. | $102.66 | 2022-2025 | |
| Genentech USA, INC. | $98.91 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Supernus Pharmaceuticals, INC. | $97.91 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Menard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.